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Abstract
Background: Mesenchymal stromal cells (MSCs) are considered to have a modest benefit on left ventricular
ejection fraction (LVEF) in patients with acute myocardial infarction (AMI). However, the optimal injection timing
and dose needed to induce beneficial cardiac effects are unknown. The purpose of this meta-analysis was to
identify an optimal MSC transplantation time and cell dose in the setting of AMI to achieve better clinical
endpoints.
Methods: The authors conducted a systematic review of studies published up to June 2016 by searching PubMed,
EMBASE, MEDLINE, and the Cochrane Library for relevant randomized controlled trials (RCTs).
Results: Eight prospective RCTs with 449 participants were included. The pooled results revealed that patients in
the MSC group had no significant increase in LVEF from baseline compared with that in the control group (1.47%
increase, 95% confidence interval (CI) −4.5 to 7.45; I2 = 97%; P > 0.05). A subgroup analysis was conducted to explore
the results according to differences in transplantation time and dose of MSCs injected. For transplantation timing,
the LVEF of patients accepting a MSC infusion within 1 week was significantly increased by 3.22% (95% CI 1.31 to 5.
14; I2 = 0; P < 0.05), but this increase was insignificant in the group that accepted an MSC infusion after 1 week (−0.
35% in LVEF, 95% CI −10.22 to 9.52; I2 = 99%; P > 0.05). Furthermore, patients accepting a MSC dose of less than 107
cells exhibited an LVEF improvement of 2.25% compared with the control (95% CI 0.56 to 3.93; I2 = 9%; P < 0.05).
Combining transplantation time and cell dose indicates that a significant improvement of LVEF of 3.32% was
achieved in the group of patients injected with <107 MSCs within 1 week (95% CI 1.14 to 5.50; I2 = 0; P = 0.003).
Conclusions: Transplantation time and injected cell dose are key factors that determine the therapeutic effect of
stem cell therapy. The injection of no more than 107 MSCs within 1 week for AMI after percutaneous coronary
intervention might improve left ventricular systolic function. Further studies on the mechanism and the
effectiveness of MSCs for long-term therapy are warranted.
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Background
Stem cell transplantation in the setting of acute myocar-
dial infarction (AMI) has been implemented for decades
[1, 2]. Although early revascularization can save part of
the ischemic myocardium, non-renewable necrotic myo-
cardial cells call for stem cell therapy to provide changes
in reducing mortality rate and improving quality of life
[3, 4]. Mesenchymal stromal cells (MSCs) serve as a
major cell candidate and a promising stem cell type to
improve cardiac function following transplantation to in-
farcted myocardium [5, 6].
Chen et al. were the first to report that MSC trans-
plantation in AMI patients could increase left ventricular
ejection fraction (LVEF) by 12% [7]. The results
prompted an increase in the numbers of centers that use
the therapeutic potential and safety of MSCs in AMI in
the context of regenerative therapy and immune modu-
lation [8, 9]. However, most of the reported studies were
small or had conflicting outcomes [10–12].
Bone marrow stem cell transfer is an emerging therapy
for AMI patients. Several meta-analyses have indicated
the effectiveness and safety of bone marrow stem cells in
improving LVEF, but no consistent results are available
regarding the optimal transplantation time, and no data
on dosage have been obtained [13–17]. The above meta-
analyses [13, 16, 17] included trials using hybrid cells as
the study group, which might hide the effectiveness of
certain stem cell types. Considering that varying the time
interval from stem cell harvest to reinfusion may influ-
ence cytoactivity and the cell dosage may affect myocar-
dial recovery, the authors conducted a meta-analysis of
current randomized controlled trials (RCTs) using MSCs
for AMI to investigate the effectiveness of MSC trans-
plantation in AMI patients and to study the effects of
transplantation time and transplant dose of MSCs; the




This systematic review was conducted according to the
methods recommended by published guidelines for
meta-analyses [4]. The authors attempted to address the
following questions: within which time period and using
which cell dose will MSC transplantation provide the
most benefit for AMI patients?
Data source and search strategy
Relevant studies were identified by searching PubMed,
MEDLINE, the Cochrane Library (to June 2016), and
internet-based sources of information on cardiology.
The following search terms were used, alone or in com-
bination [18]: mesenchymal stromal cells, mesenchymal
stem cells, stem cells, stem cell, stromal cells, stromal cell,
acute myocardial infarction, myocardial infarction, cor-
onary artery disease, cardiac repair. No language limit
was applied. The search was limited to RCTs and the
transplantation of MSCs only in the test group.
Eligibility criteria
Inclusion criteria for the randomized AMI groups in the
present analysis were as follows: (1) RCTs; (2) transplanted
stem cells were limited to the MSC cell type, but the cell
dose or administration route were unrestricted; (3) studies
that were conducted in patients with ST-segment or non-
ST-segment elevation myocardial infarction treated with
primary percutaneous coronary intervention (PCI) after
AMI; (4) studies that used cell-based therapy within
3 months after PCI in AMI patients; (5) studies that in-
volved participants receiving standard therapy in both cell
groups and control arms while the control arm did not re-
ceive stem cells; and (6) studies that did not restrict MSC
resources in terms of origin (human bone marrow, human
umbilical cords, or adipose tissue) but that did not use
granulocyte colony-stimulating factor (G-CSF).
Data extraction and quality assessment
The authors analyzed the reports published for each
trial, and standard information was entered into a
spreadsheet. Two investigators independently extracted
data from the studies, including publication date, study
design, sample size, method used to assess myocardial
function, patient baseline characteristics, cell resource
and dose, delivery route, primary intervention, baseline
LVEF, time from intervention to cell infusion, cardiac
medication, follow-up duration, and change in LVEF, left
ventricular end-systolic volume (LVESV), and left
ventricular end-diastolic volume (LVEDV) outcomes.
Echocardiography, single-photon emission computed
tomography, positron emission computed tomography,
and cardiac magnetic resonance imaging (MRI)
functional data were available; echocardiography data
were preferentially used unless MRI data were available
[19–21]. In case of missing or unclear data for the pri-
mary or secondary endpoints, at least two separate at-
tempts were made at least 3 weeks apart to clarify the
data by contacting the primary authors. When any dis-
agreement occurred between the investigators, a third
reviewer independently adjudicated based on the data.
Outcomes
The primary endpoints were to find the optimal injected
dose and its timing to induce better LVEF from baseline
to follow-up.
Quality assessment
Study quality was assessed based on the use of appropri-
ate randomization, concealment of treatment allocation,
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similarity of treatment groups at baseline, the provision
of a description of the eligibility criteria, completeness of
the follow-up duration, and the use of an intention-to-
treat analysis. The quality of the studies was assessed in
accordance with the Jüni criteria [22], using a risk scale
to evaluate the quality as high, low, or unclear risk as
implemented in RevMan 5.3 software.
Data synthesis and meta-analysis
Statistical analyses of LVEF were performed using a
comprehensive meta-analysis. Mathematical and com-
puter modeling were also used to optimize management
[23–25]. Data were calculated using the inverse variance
formula. For continuous parameters, weighted mean dif-
ferences (WMDs) were calculated using end of trial
mean values, their corresponding standard deviations,
and treatment arm size. Moreover, the data were ana-
lyzed using 95% confidence intervals (CI). A random-
effect model was used. A forest plot was used to show
the WMD and 95% CI for each study. The percentage of
variability across studies that was attributable to hetero-
geneity beyond chance was estimated using I2 and Q sta-
tistics. The Q statistic was considered significant if P <
0.05, and I2 > 50% indicated high heterogeneity. Sub-
group analyses were conducted based on transplantation
time (<1 week or 1–4 weeks) after PCI and injected
MSC dose (<107 cells or >107 cells). In studies reporting
the mean ± standard error, the standard deviation of the
required data was calculated using a previously used
standardized formula [26]. A two-sided P value <0.05
was considered statistically significant. Statistical ana-
lyses were performed using Review Manager software
(RevMan, version 5.3) and SPSS software (version 12).
Sensitivity analyses and publication bias
Considering the small number of studies in this pooled
analysis, the authors tested the robustness of our results
in sensitivity analyses by omitting one study at a time.
Potential publication bias was assessed using the Egger
test and was represented graphically using Begg funnel
plots, which are based on an adjusted rank correlation
test.
Results
Study identification and selection
A flow diagram depicting the overall search strategy is
demonstrated in Fig. 1. Of 1091 articles retrieved during
the initial search (371 from PubMed, 353 from MED-
LINE, 342 from EMBASE, and 25 from the Cochrane
Database), 702 were duplicates, 120 were excluded after
title and abstract screening, 123 were animal experi-
ments, 46 were reviews, and 18 were meta-analyses. The
remaining 82 studies were retrieved in full for detailed
evaluation. Twenty-seven were excluded due to etiology
other than AMI, 21 used other cell types included with
bone marrow stem cells, 19 were excluded due to
unrelated outcomes, three were non-RCTs, three in-
cluded G-CSF stimulation, one lacked a control group,
and one included coronary artery bypass grafting. Eight
RCTs with a total of 449 patients were eligible for review
[7, 10, 12, 27–31].
Study characteristics and study quality
The eight included studies involved patients with AMI,
including patients with both ST-elevated and non-ST el-
evated myocardial infarction treated with primary PCI.
The methodological quality of the enrolled studies was
assessed using key indicators as shown in Table 1. The
randomization methods used in the included trials were
defined as being of low risk, except one which was re-
ported as being at high risk of allocation concealment
[30]. In addition, at least 50% (ranging from 50 to 75%)
of the randomized patients were analyzed with regard to
the outcomes of the binding assessment. Almost all the
included trials were defined as being of low risk of in-
complete outcome data and selective reporting. The
main characteristics of the trials and patients are sum-
marized in Tables 2 and 3. The trials were published be-
tween 2004 and 2015. The sample sizes ranged from 14
to 116, with follow-up ranging from 1 to 24 months. Of
the eight trials that were identified, five were multicenter
studies [10, 27–30]. The average participant age in the
eight trials ranged from 48 to 59 years. Most participants
were male. The mean age and gender were similar be-
tween the control and treatment groups within each
study (P > 0.05). Most studies used a 1:1 randomization
Fig. 1 Flow diagram of enrolled trials. Flow diagram of randomized
controlled trials (RCTs) selected for the meta-analysis of acute myocardial
infarction with mesenchymal stromal cells therapy. G-CSF granulocyte
colony-stimulating factor
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scheme. Seventy-five percent (6/8) of the trials used
bone marrow-derived MSCs; one used MSCs from um-
bilical cord [27] and one used MSCs from adipose tissue
[12]. One trial reported an initial LVEF of less than 45%
[31], and two used intravenously injected MSCs [10, 29].
Considerable heterogeneity existed in the timing of cell
transplantation after PCI (from within 24 h after trans-
plantation to 25 days after) and in the number of cells
administered (ranging from 3 × 106 to 8 × 109 cells).
Influence of transplantation time and cell dose on LVEF
The pooled comparison of the change in LVEF is shown
in Fig. 2. The results revealed that LVEF was not statisti-
cally higher than baseline in patients in the MSC group
compared with those in the control (1.47% increase, 95%
CI −4.50 to 7.45; P = 0.63). A considerable degree of
heterogeneity was observed (I2 = 97%). Planned subgroup
and sensitivity analyses were conducted to further ex-
plore the statistical heterogeneity.
Subgroup analyses
Transplantation time
When comparing cell infusion time, greater LVEF im-
provement was observed in the groups with patients
who were injected with MSCs within 1 week (3.22% in-
crease in LVEF, 95% CI 1.31 to 5.14; I2 = 0%; P = 0.001)
compared with that in the control at 6 months of
follow-up. However, the results were not statistically sig-
nificant for groups involving the infusion of MSCs more
than 1 week after PCI (−0.35%, 95% CI −10.22 to 9.52;
I2 = 99%; P = 0.94 compared with the control) (Fig. 3a).



















Chen et al. 2004 [7] L L U U L L
Chullikana et al. 2015 [10] L L L L L L
Gao et al. 2013 [28] L L L H L L
Gao et al. 2015 [27] L L L L L L
Hare et al .2009 [29] L L L L U L
Houtgraaf et al. 2012 [12] L L L L L L
Lee et al. 2014 [30] L H H H L L
Wang et al. 2014 [31] L L U U L L
H high risk, L low risk, U unclear risk (Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0)

















RCT Single-center AMI PCI Yes 69 (34/35) LVEF, LVESV,
LVEDV
3, 6 0 (0)
Chullikana et al.
2015 [10]
RCT Multicenter AMI PCI Yes 20(10/10) LVEF, Infarct size,
Perfusion defect
6, 24 4 (20)
Gao et al.
2013 [28]
RCT Multicenter AMI PCI Yes 43 (21/22) LVEF, LVESV,
LVEDV, WMSI, LVFS
6, 12, 24 4 (9)
Gao et al.
2015 [27]
RCT Multicenter AMI PCI Yes 116 (58/58) LVEF, LVESV,
LVEDV, WMSI, LVFS
1, 4, 12, 18 4 (3)
Hare et al.
2009 [29]
RCT Multicenter AMI PCI Yes 60 (39/21) LVEF, LVESV,
LVEDV
1, 2, 3, 6, 12 0 (0)
Houtgraaf et al.
2012 [12]





RCT Multicenter AMI PCI NR 69 (33/36) LVEF, LVESV,
LVEV, WMSI
1, 2, 6 11 (16)
Wang et al.
2014 [31]
RCT Single-center AMI PCI Yes 58 (28/30) LVEF 1, 3, 6 3 (5)
AMI acute myocardial infarction, LVEDV left ventricular end-diastolic volume, LVEF left ventricular ejection fraction, LVESV left ventricular end-systolic volume, LVFS
left ventricular fractional shortening, MSC mesenchymal stromal cell, NR not reported, PCI percutaneous coronary intervention, RCT randomized controlled trial,
WMSI wall motion score index
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Transplantation dose
In the trials involving an injected cell dose of less than
107, LVEF was improved by 2.25% compared with the
control (95% CI 0.56 to 3.93, I2 = 9%; P = 0.009). How-
ever, MSCs at doses of greater than 107 did not exhibit
any LVEF benefit (0.62%, 95% CI −9.69 to 10.92; I2 =
98%; P = 0.91) (Fig. 3b).
Combination of transplantation timing and dosage
Injection timing and the dose were also analyzed in
combination (Fig. 4). LVEF improvements were only
observed in the group in which MSCs were injected
within 1 week and at a cell dose of less than 107; this
combination resulted in a significant increase in LVEF
of 3.32% (95% CI 1.14 to 5.50; I2 = 0%; P = 0.003);
other transplantation timing and dose combinations
showed no benefit in terms of LVEF (2.88%, 95% CI
−1.13 to 6.90, I2 = 0%; P = 0.16 for MSC injection
within 1 week with a cell dose of greater than 107 vs.
control; -0.8%, 95% CI −15.33 to 13.73, I2 = 99%; P =
0.91 for MSC injection within 1–4 weeks with a cell
dose of greater than over 107 vs. control).
Publication bias and sensitivity analyses
The trial reported by Wang et al. [31] fell outside the
Begg funnel plot, indicating publication bias. Using a
sensitivity analysis, the same trial also exhibited hetero-
geneity. I2 decreased from 95% to 75% and LVEF in-
creased from 1.47% to 3.93% in the MSC group (P =
0.001 compared with the control) when the data from
Wang et al. [31] were excluded.
Discussion
The main result of this analysis is that MSC therapy
might only achieve better LVEF improvement within a
specific transplantation time window and when using an
optimal MSC dose.
The efficacy of stem cell therapy in patients with AMI
has long been discussed. Among the candidate cell
types, MSCs are suggested to achieve better global LVEF,
thus reducing infarct size and left ventricular remodeling
compared with other cell types, such as CD34+/CD133+
and bone marrow mononuclear cells, in AMI [32, 33].
Interestingly, researchers are often uncertain about the
timing and MSC dose that should be administered to
achieve better LVEF in AMI patients. However, data
Table 3 Patients and procedural characteristics of included trials
Study Mean age (years) Male (%) Baseline LVEF (%)
(mean ± SD)
Time from PCI to
MSC therapy (days)




Chen et al. 2004 [7] 58 95.7 41.85 ± 8.3 18.3 BM 4.8–6 × 1010b IC
Chullikana et al. 2015 [10] 48 90.0 43.25 ± 4.01 2 BM 2 × 106 IV
Gao et al. 2013 [28] 57 93.0 50.71 ± 1.5 17.1 BM 3.08 × 106 IC
Gao et al. 2015 [27] 57 94.6 51.51 ± 0.95 6.2 Umbilical cord 6 × 106 IC
Hare et al. 2009 [29] 58 71.7 49.81 ± 10.25 <7 BM 80 × 106 IV
Houtgraaf et al. 2012 [12] 59 78.6 45.36 ± 2.73 <1 Adipose tissue 1.74 × 106 IC
Lee et al. 2014 [30] 54 75.4 49.57 ± 8.63 25 BM 72 × 106 IC
Wang et al. 2014 [31] 57 60.3 28.70 ± 4.33a 15 BM 100 × 106b IC
aHighlights a considerable low baseline LVEF; bhighlights a significantly higher number of cells
BM bone marrow, IC intracoronary, IV intravascular, LVEF left ventricular ejection fraction, PCI percutaneous coronary intervention, SD standard deviation,
Fig. 2 The effect of MSC therapy on left ventricular systolic function. Forest plot of weighted mean difference on LVEF compared with control. CI
confidence interval, IV inverse variance, MSC mesenchymal stromal cell, SD standard deviation
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addressing this issue are contradictory: Liu et al. re-
ported that various doses of stem cells (hybrid cells) did
not influence LVEF improvement in AMI [32], but other
investigators have suggested that beneficial effects might
only be achieved when higher numbers (>108) of stem
cells are infused [34, 35]. Thus, this meta-analysis
addresses the optimal time window and dose of MSCs
administered to AMI patients for the first time. No sig-
nificant further LVEF increase was observed in the MSC
group compared with the controls in all trials, and high
heterogeneity (I2 = 97%) was noted among the trials. The
authors then explored whether the transplantation time
and/or cell dose used explained the insignificant findings
regarding LVEF.
Effect of timing and MSC dose on LVEF
In the subanalysis of transplantation time, LVEF was in-
creased by 3.22% in the MSC group compared with the
controls when the cells were injected within 1 week after
PCI. However, no benefit for LVEF over the controls was
observed when MSCs were administered after more than
1 week. This finding is consistent with other randomized
trials studying cell administration time using bone
marrow stem cells that claimed that the best benefits for
global LVEF were achieved when administering cell ther-
apy between 4 and 7 days after AMI [36, 37]. Stem cells
that are infused immediately after AMI might cause ex-
cessive obstruction and dysfunction in the microvascular
bed, thereby creating a hostile environment due to
Fig. 3 Impact of transplantation time and dose of MSCs on LVEF. a Forest plot showing the impact of transplantation timing of MSCs (<1 week
or >1 week) on LVEF. b Forest plot showing the impact of transplantation dose of MSCs (<107 cells or >107 cells) on LVEF. CI confidence interval,
IV inverse variance, MSC mesenchymal stromal cell, SD standard deviation
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inflammation of the myocardium potentially limiting cell
retention and engraftment [38]. However, preclinical tri-
als in which stem cells were administered within 1 week
but not immediately indicated that administering stem
cells served to prevent cardiomyocyte loss by secreting
anti-apoptotic and anti-inflammatory paracrine factors
or by inducing an angiogenic effect [39–41]. Moreover,
the refusion time of MSCs was determined from PCI to
cell administration, which is different from measuring
the time interval starting at AMI. Considering that PCI
is carried out as early as possible after AMI in clinical
emergencies, the intracoronary or intravascular adminis-
tration of stem cells may save viable myocardium after
the reperfusion of infarcted myocardium. More clinical
data and basic research are needed to address this issue.
Regarding the effects of cell dose on LVEF improve-
ment, the results found in this study showed that an
MSC dose of less than 107 can provide a significant
beneficial effect on LVEF, while higher doses (more than
107) of MSCs exhibit no LVEF increase compared with
the controls. However, several studies have reported that
patients administered with a higher number (more than
108 cells) of bone marrow stem cells exhibit a greater
LVEF benefit [42, 43]. However, those who advocate
using the standard number of infused cells have sug-
gested that MSCs, which are larger (~22–25 μm in
diameter) than capillaries (~8–10 μm in diameter), may
be associated with a risk of obstructing microvessels and
might compromise blood flow when injected intracoro-
narily [36, 44]. Gao et al. reported that one patient
suffered from a serious complication involving coronary
artery occlusion and subsequent lack of flow during the
intracoronary procedure when injecting a higher dose
(3.08 × 106) of MSCs [28]. Vulliet et al. also reported the
occurrence of coronary embolisms leading to acute myo-
cardial ischemia and subacute myocardial microinfarc-
tions after the intracoronary injection of MSCs in a dog
model [45].
When studying injection timing and dose in combin-
ation, a significant impact on LVEF (an increase of
3.32%) was found in a subgroup combining a transplant-
ation time within 1 week and an injected dose of less
than 107 cells (95% CI 1.14 to 5.50); transplanting the
cells within 1 week and injecting more than 107 cells re-
sulted in a slight improvement of LVEF, whereas admin-
istering the cells at more than 1 week and injecting
more than 107 cells had the opposite effect on LVEF.
However, these results should be cautiously interpreted
as only two trials were included in this study, and one
used a small patient samples. Notably, the data from
Gao et al. markedly demonstrated a similar result with
strong significance [27].
As we mentioned above, the preliminary results should
be interpreted with caution. The potential of stem cell
therapy for cardiac repair may be influenced not only by
cell dosage but also by patient status, such as the level of
basic ejection fraction (28.7 ± 4.33 to 51.51 ± 0.95 in the
included studies). Moreover, the inter-study differences
in patient age and gender may affect therapeutic effect-
iveness indicating that aging patients who are likely to
Fig. 4 Impact of combining transplantation timing and dosage of MSCs on LVEF. Time and dose was divided into three subgroups: <107 MSCs
were injected within 1 week of AMI, >107 MSCs were injected within 1 week of AMI, and >107 MSCs were injected after 1 week of AMI. CI
confidence interval, IV inverse variance, MSC mesenchymal stromal cell, SD standard deviation
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suffer from impaired endothelium might exhibit inad-
equate physiological angiogenesis responses to ischemia
and females may benefit more from stem cell therapy
than males [46]. In addition, we suspect that the source
and purity of MSCs can affect therapeutic response.
Mechanisms of the therapeutic effect of MSCs
It has been widely demonstrated that the four main
mechanisms of action for the cardioreparative effects of
MSC therapy are as follows: (1) in vivo reduction of
myocardial fibrosis; (2) stimulation of angiogenesis; (3)
restoration of contractile function through engraftment
differentiation; and (4) stimulation of endogenous car-
diac stem cells to proliferate and differentiate [47]. Accu-
mulating evidence has indicated that the paracrine
mechanism is the predominant cause of the beneficial
effects exerted by MSCs and is based on a multitude of
bioactive molecules, including cytokines, chemokines,
and growth factors [48]. These molecules contribute to
reducing fibrosis through suppressing the proliferation
of fibroblasts and promoting their metalloproteinase se-
cretion, stimulating the angiogenesis, proliferation and
differentiation of host cells, and recruiting endogenous
cardiac stem cells. In addition, MSCs can alter endothelial
cell behavior and differentiate into endothelial cells in
vitro or into cardiomyocytes in vivo. Moreover, implanted
MSCs can regulate the proliferation and differentiation of
endogenous cardiac stem cells and enhance myocyte cell
cycling via cell–cell interaction, thereby homing to the in-
jury site to repair injured myocardium and boost angio-
genesis for myocardial repair [49]. In addition, it has been
reported that direct cellular mechanisms involving exo-
somes, mitochondrial transfer, connexin43, etc., can con-
vincingly explain the effects observed in preclinical and
clinical studies [47]. Moreover, studies also indicate that
the mesenchymal–endothelial transition appears to have
an important physiological role in cardiac repair due to
possible neovascularization [50].
Limitations
This study has several limitations. First, the scope of the
results is limited by the small number of trials included.
Ideally, more observation parameters regarding end-
points, such as LVESV, LVEDV, and the wall motion
score index, could be included to evaluate cardiac struc-
ture and function when more RCTs are conducted. Sec-
ond, as the authors mentioned previously, the results
describing the combination of cell injection timing and
dose were drawn from only two trials; this might reduce
the power of the study to draw solid conclusions. How-
ever, a separately conducted meta-analysis on timing and
dose including more trials is expected to draw the same
conclusions. Finally, a trial from Wang et al. applied
MSCs in patients with severely impaired LVEF (<35%),
and this might have affected the inhomogeneity of the
meta-analyses. Detailed conclusions regarding baseline
LVEF and LVEF changes during follow-up require sup-
port from more data.
Conclusion
Transplantation time and injected cell dose are key fac-
tors that determine the therapeutic effect of stem cell
therapy. No more than 107 MSCs injected within 1 week
for AMI after PCI might represent the optimal time win-
dow and dose for improving left ventricular systolic
function; these results will hopefully provide a reference
for future research and clinical studies.
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